Share: Facebook Twitter LinkedIn
Activity Provided By:

Relias LLC

PER® Postgame™: MS Meeting Updates " Integrating the Latest Data to Optimize Care in the COVID-19 Era

Access Activity

Overview / Abstract:

Target Audience
This educational activity is directed toward MS specialists, community neurologists, neuroimmunologists, specialty NPs, PAs, RNs, and other members of the MS care team.

Activity Overview
Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS) characterized by demyelination and neurodegenerative progression. Most MS therapies target various immune cells involved in the inflammatory cascade. The recent COVID-19 pandemic has created additional concerns for patients with MS who may be exposed to the causative agent of COVID-19 or develop this potentially life-threatening disease. COVID-19 vaccination is recommended for MS patients; however, questions have been raised about vaccine safety and efficacy in patients with immune-mediated conditions such as MS and the impact of immunosuppressive or immunomodulatory disease-modifying therapies (DMTs).

The PER® Postgame™ is an innovative and unique online activity by PER®. It is an in-depth, engaging data recap program focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2022 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and Consortium of Multiple Sclerosis Centers (CMSC) annual meetings.

Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Describe currently available molecular biomarkers/other key indicators of MS and their role in early differential diagnosis and monitoring disease progression
Evaluate recent efficacy and safety data of current and emerging DMTs for the optimal treatment of patients with MS
Discuss the impact of DMTs on anti-SARS-CoV-2 vaccine response in patients with MS
Implement timely, evidence-based strategies to maximize immune response to anti-SARS-CoV-2 immunotherapy in patients with MS exposed or infected with SARS-CoV-2
Design COVID-19 prevention/treatment plans that minimize risk of SARS-CoV-2 infection while maintaining efficacy of DMTs in patients with MS

Expiration

Dec 20, 2023

Discipline(s)

Nursing CNE, Physician CME

Credits / Hours

2.0

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Erin E. Longbrake, MD, PhD
Assistant Professor
Department of Neurology
Yale University
New Haven, CT

Ilya Kister, MD, FAAN
Professor, Department of Neurology
Director, Multiple Sclerosis Fellowship
NYU Grossman School of Medicine
Director, Neuromyelitis Optica Treatment and Research Program
NYU Langone Medical Center
New York, NY

Joseph J. Sabatino Jr, MD, PhD
Assistant Professor
Department of Neurology
Weill Institute for Neurosciences
University of California, San Francisco
San Francisco, CA

Sponsors / Supporters / Grant Providers

Physicians’ Education Resource®, LLC; Genentech, Inc.

Keywords / Search Terms

Relias LLC Neurology, Primary Care, Multiple Sclerosis Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map